Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04572815 · ClinicalTrials.gov registry record · Phase 2
Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant
A Phase 2 study of Hematopoietic and Lymphoid System Neoplasm and Hematologic and Lymphocytic Disorder, sponsored by Fred Hutchinson Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 4
- Study locations
NCT04572815 is a Phase 2 study of Hematopoietic and Lymphoid System Neoplasm and Hematologic and Lymphocytic Disorder that is active but no longer recruiting, run by Fred Hutchinson Cancer Center. The registered enrollment target is 116 participants, below the 1,355-participant average among 31 other Hematopoietic and Lymphoid System Neoplasm trials with a reported enrollment target (91% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT04572815, a Phase 2 study of Hematopoietic and Lymphoid System Neoplasm and Hematologic and Lymphocytic Disorder, is active but no longer recruiting, sponsored by Fred Hutchinson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies how well ustekinumab works in preventing acute graft-versus-host disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving ustekinumab after the transplant may help prevent acute graft-versus-host disease by controlling the body's immune response. Funding Source- FDA OOPD.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- DRUG Placebo Administration
- BIOLOGICAL Ustekinumab
Study Locations (4)
California
- City of Hope Comprehensive Cancer Center, - Duarte
Florida
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
New York
- Roswell Park Cancer Institute - Buffalo
Washington
- Fred Hutch/University of Washington Cancer Consortium - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-05-14 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04572815
The ClinicalTrials.gov registry entry for NCT04572815 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 116 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,355-participant average among 31 other Hematopoietic and Lymphoid System Neoplasm trials with a reported enrollment target (91% lower). The listed sponsor is Fred Hutchinson Cancer Center, which has 483 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hematopoietic and Lymphoid System Neoplasm appearing as the primary indexed condition, and to 4 interventions - of which Quality-of-Life Assessment is the first listed.
NCT04572815 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT04572815 about?
NCT04572815 is a clinical study titled "Ustekinumab for the Prevention of Acute Graft-versus-Host Disease After Unrelated Donor Hematopoietic Cell Transplant". This phase II trial studies how well ustekinumab works in preventing acute graft-versus-host disease after unrelated donor hematopoietic cell transplant. Sometimes the transplanted cells from a donor can attack the body's normal tissues (called graft-versus-host disease). Giving ustekinumab after th...
What is the current status of trial NCT04572815?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2021-05-14. Estimated completion is 2027-06-30.
What conditions does trial NCT04572815 study?
This clinical trial studies the following conditions: Hematopoietic and Lymphoid System Neoplasm, Hematologic and Lymphocytic Disorder.
What interventions are being tested in trial NCT04572815?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Placebo Administration (DRUG), Ustekinumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04572815?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04572815 being conducted?
This trial has 4 study locations across California, Florida, New York, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematopoietic and Lymphoid System Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Community-Based Physical Activity Intervention for Underserved Cancer Survivors
RECRUITING · NA
-
Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial
RECRUITING · NA
-
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
RECRUITING · Phase 1
Explore more on PlainTrial
Hematopoietic and Lymphoid System Neoplasm
All registered trials for this condition
Hematologic and Lymphocytic Disorder
All registered trials for this condition
California
All trials with a study site in California
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.